Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Event terms that represent the same medical concept or condition were grouped together and reported as a single adverse reaction in Table 3. Terms actually reported in the study up to the data cut-off date and contributing to the relevant adverse reaction are indicated in parentheses, as listed below.
* The patients described reflect exposure to XALKORI in 1,669 patients with ALK+ advanced NSCLC in 2 randomised Phase 3 studies and in 2 single-arm studies, and in 53 patients with ROS1+ advanced NSCLC who participated in a single-arm study (for a total of 1,722 patients).1
XALKORI as a monotherapy is indicated for:1
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020